Activating mutations in the epidermal growth factor receptor (EGFR) gene is a relatively frequent event in patients with advanced non-squamous non-small-cell lung cancer (NSCLC), occurring in 15 to 50% of cases. This evidence concerns the gene EGFR and non-small cell squamous lung carcinoma.